Rights and permissions
About this article
Cite this article
Dolasetron preferred for PONV prophylaxis. Inpharma Wkly. 1196, 7 (1999). https://doi.org/10.2165/00128413-199911960-00012
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128413-199911960-00012